Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 2/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1900240 | 0.92 | VNN1 (0.41) | VNN1TACR3SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL1908041 | 0.87 | CYP3A4 (0.37) | VNN1TACR3SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL14118764 | 0.85 | TACR3 (0.42) | TACR3MAPTCYP3A4ALOX15CYP2C8 | |
| SCHEMBL14118761 | 0.84 | IP6K1 (0.41) | TACR3CYP3A4CYP2C8PDE2AALDH1A1 | |
| SCHEMBL1905065 | 0.81 | AKT1 (0.48) | ALOX15ALDH1A1HSD17B10 | |
| SCHEMBL1904761 | 0.81 | VNN1 (0.37) | VNN1TACR3SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL1904881 | 0.80 | AKT1 (0.42) | TACR3CYP3A4CYP2C8PDE2ASCN9A | |
| SCHEMBL1534546 | 0.79 | PLA2G2A (0.42) | TACR3MAPTCYP3A4ALOX15CASP1 | |
| SCHEMBL1902270 | 0.79 | TACR3 (0.38) | VNN1TACR3SMN1; SMN2MAPTALOX15 | |
| SCHEMBL1903074 | 0.78 | MAPT (0.36) | SMN1; SMN2MAPTCYP3A4ALOX15CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | AKT1, AKT2, AKT3 | VNN1 3559/4885TACR3 3761/4885SMN1; SMN2 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.